COST EFFECTIVENESS MODEL ON FOUR PREVENTIVE TREATMENT FOR CLOSTRIDIOIDES DIFFICILE INFECTION RECURRENCE FROM A US PAYER PERSPECTIVE

被引：0
|
作者：
Gomez-Lumbreras, A. [1 ]
Schmutz, H. [1 ]
Tawfik, A. G. [1 ]
Malone, D. C. [1 ]
机构：
[1] Univ Utah, Coll Pharm, Salt Lake City, UT USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE3
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Four Common Diagnostic Methods for Clostridioides difficile Infection
    Xuan, Si
    Zangwill, Kenneth M.
    Ni, Weiyi
    Ma, Junjie
    Hay, Joel W.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (04) : 1102 - 1110
  • [2] Cost-Effectiveness Analysis of Four Common Diagnostic Methods for Clostridioides difficile Infection
    Si Xuan
    Kenneth M. Zangwill
    Weiyi Ni
    Junjie Ma
    Joel W. Hay
    Journal of General Internal Medicine, 2020, 35 : 1102 - 1110
  • [3] Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan
    Okumura, Hiroyuki
    Ueyama, Maki
    Shoji, Shingo
    English, Marci
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2020, 26 (06) : 611 - 618
  • [4] Cost-effectiveness of overactive bladder treatments: from the US payer perspective
    Murray, Brian
    Hessami, Sam H.
    Gultyaev, Dmitry
    Lister, Johanna
    Dmochowski, Roger
    Gillard, Kristin Khalaf
    Stanisic, Sanja
    Tung, Amy
    Boer, Robert
    Kaplan, Steven
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (01) : 61 - 72
  • [5] COST EFFECTIVENESS OF ONABOTULINUMTOXINA VERSUS PTNS AND SNS FOR THE TREATMENT OF OVERACTIVE BLADDER FROM THE US PAYER PERSPECTIVE
    Hepp, Z.
    Yehoshua, A.
    Gultyaev, D.
    Lister, J.
    VALUE IN HEALTH, 2016, 19 (03) : A130 - A130
  • [6] Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection
    Chen, Jiahe
    Gong, Cynthia L.
    Hitchcock, Matthew M.
    Holubar, Marisa
    Deresinski, Stanley
    Hay, Joel W.
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (10) : 1448 - 1454
  • [7] Correction: Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England
    Tom Bromilow
    Hayden Holmes
    Laura Coote
    Sam Woods
    Joshua Pink
    PharmacoEconomics - Open, 2023, 7 : 861 - 861
  • [8] COST-EFFECTIVENESS OF SOLIFENACIN FOR THE TREATMENT OF OVERACTIVE BLADDER FROM A US PRIVATE PAYER AND MEDICARE ADVANTAGE PERSPECTIVE
    Ng, D. B.
    Wielage, R.
    Klein, T. M.
    Klein, R. W.
    Gooch, K.
    VALUE IN HEALTH, 2016, 19 (07) : A519 - A519
  • [9] Cost-effectiveness of overactive bladder treatments from a US commercial and payer perspective
    Murray, Brian
    Miles-Thomas, Jennifer
    Park, Amy J.
    Nguyen, Victor B.
    Tung, Amy
    Gillard, Patrick
    Lalla, Anjana
    Nitti, Victor W.
    Chermansky, Christopher J.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (02)
  • [10] COST EFFECTIVENESS OF MOMELOTINIB VS OTHER TREATMENTS FOR MYELOFIBROSIS FROM A US PAYER PERSPECTIVE
    Liu, T.
    Purser, M.
    Gong, C.
    Elsea, D.
    Niehoff, N.
    Dlotko, E.
    Migliaccio-Walle, K.
    Samyshkin, Y.
    VALUE IN HEALTH, 2024, 27 (06) : S112 - S112
12345